BEAM
Bearish signalScored 2026-10-22 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Beam Therapeutics Inc.
- Nom
- Beam Therapeutics Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $2.5B
- Employés
- 540
- PDG
- John Evans
- Site web
- https://www.beamtx.com
- Marché
- ALLOCLLSCRBUCRSPDTILEDIT
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 50 000 titres (~1 188 745,00 $ US)
- Insiders
- Evans John M.
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$1,193,310
Avg sell (VWAP, 90d window) $23.78 vs last close $23.79 (+0.1%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$1,193,310 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-16
- Liquidity
- Liquid $40,453,312/day · 20d vol
- Last synced
-
2026-10-26 21:10:10
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-16 | Evans John M. | Sell · S · 10b5-1 | 25,000 | $23.98 | $599,595 | Form 4 |
| 2026-10-15 | Evans John M. | Sell · S · 10b5-1 | 25,000 | $23.57 | $589,150 | Form 4 |
| 2026-10-01 | Cavanagh Bethany J | Sell · S · 10b5-1 | 187 | $24.41 | $4,565 | Form 4 |
| 2026-07-27 | Simon Amy | Sell · S · 10b5-1 | 16,667 | $25.74 | $429,037 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-10-22 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
BEAM presents a high-burn, pre-profitability profile with deeply negative operating and free cash flow margins, making it structurally dependent on external capital at a time when its catalyst score is weak (25) and…
The first sentence of the analysis written for BEAM on 2026-10-22 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $1.6M) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $1.6M) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 13.09 · operating margin -275% — readings disagree
Suggested stop 22.72, nearest stored support minus 0.5 ATR(4.5% under the last close). Reward/risk to the next stored resistance is 0.27. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-19 Insider Selling: Beam Therapeutics (NASDAQ:BEAM) CEO Sells $589,250.00 in Stock Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) CEO John Evans sold 25,000 shares of the business''s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $23.57, for a total transaction of $589,250.00. Following the sale, the chief executive officer owned 1,047,205 shares in the company, valued
- 2026-10-17 Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead? Cathie Wood owns Beam shares worth roughly $220 million, at the stock''s current price. All of the company''s revenue is collaboration revenue.
- 2026-10-15 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. ("Beam" or the "Company") (NASDAQ: BEAM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
- 2026-10-13 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. (“Beam” or the “Company”) (NASDAQ: BEAM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
- 2026-10-13 Top 10 Powder Keg Stocks Where Short Sellers Are Sitting on a Fuse Short sellers are betting heavily against 10 stocks, and the fuse is getting shorter. Each one has more than 38% of its float sold short, with market caps above $2 billion and average daily volume above 1 million shares, according to Benzinga Pro screener data as of Oct. 12.
- 2026-10-13 Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress BEAM-301 Achieves Clinical Proof of Concept for Genetic Correction of R83C Mutation in GSDIa Initial Phase 1/2 Data Show Restoration of Endogenous Glucose Production Following a Single Treatment, with Dose-Dependent Improvements in Key GSDIa Endpoints Safety Profile of BEAM-301 Consistent with LNP-based Therapies Beam to Host Investor Webcast on Tuesday, October 27, 2026, at 8:00 a.m. ET CAMBRIDGE, Mass.
- 2026-10-08 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. ("Beam" or the "Company") (NASDAQ: BEAM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
- 2026-10-06 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. (“Beam” or the “Company”) (NASDAQ: BEAM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
- 2026-10-01 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. ("Beam" or the "Company") (NASDAQ: BEAM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
- 2026-09-29 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. (“Beam” or the “Company”) (NASDAQ: BEAM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 84.0% | -478.7% | 100.0% | -411.5% | -347.8% | |
| Ebit Margin | -25.9% | -593.1% | -34.7% | -468.9% | -458.1% | |
| Ebitda Margin | -10.0% | -558.5% | -29.4% | -445.7% | -443.8% | |
| Operating Profit Margin | -274.6% | -654.3% | -46.7% | -555.6% | -757.0% | |
| Pretax Profit Margin | -57.2% | -593.1% | -34.7% | -468.9% | -714.9% | |
| Continuous Operations Profit Margin | -57.2% | -593.1% | -35.1% | -474.5% | -714.9% | |
| Net Profit Margin | -57.2% | -593.1% | -35.1% | -474.5% | -714.9% | |
| Bottom Line Profit Margin | -57.2% | -593.1% | -35.1% | -474.5% | -714.9% | |
| Current Ratio | 13.088 | 4.823 | 5.891 | 4.888 | 5.964 | |
| Quick Ratio | 13.088 | 4.823 | 5.891 | 4.888 | 5.964 | |
| Solvency Ratio | -0.238 | -0.958 | -0.235 | -0.452 | -0.561 | |
| Cash Ratio | 3.043 | 1.549 | 2.120 | 1.041 | 2.624 | |
| Price To Earnings Ratio | -34.222 | -5.415 | -15.826 | -9.470 | -13.811 | |
| Price To Earnings Growth Ratio | 0.416 | -0.033 | 0.271 | 0.333 | -2.708 | |
| Forward Price To Earnings Growth Ratio | 0.416 | -0.033 | 0.271 | 0.333 | -2.708 | |
| Price To Earnings Diluted Ratio | -34.222 | -5.415 | -15.826 | -9.470 | -13.811 | |
| Price To Earnings Diluted Growth Ratio | 0.416 | -0.033 | 0.271 | 0.333 | -2.708 | |
| Price To Book Ratio | 2.214 | 2.783 | 2.140 | 3.733 | 6.191 | |
| Price To Sales Ratio | 19.619 | 32.138 | 5.560 | 44.949 | 98.725 | |
| Price To Free Cash Flow Ratio | -7.615 | -5.731 | -11.480 | -103.629 | -45.263 | |
| Price To Operating Cash Flow Ratio | -7.944 | -5.879 | -14.076 | 121.556 | -77.236 | |
| Debt To Assets Ratio | 0.198 | 0.146 | 0.118 | 0.133 | 0.100 | |
| Debt To Equity Ratio | 0.237 | 0.220 | 0.176 | 0.244 | 0.179 | |
| Debt To Capital Ratio | 0.192 | 0.180 | 0.150 | 0.196 | 0.152 | |
| Long Term Debt To Capital Ratio | 0.101 | 0.000 | 0.000 | 0.000 | 0.004 | |
| Financial Leverage Ratio | 1.196 | 1.505 | 1.487 | 1.829 | 1.783 | |
| Working Capital Turnover Ratio | 0.150 | 0.075 | 0.403 | 0.063 | 0.082 | |
| Operating Cash Flow Ratio | -3.560 | -1.907 | -0.726 | 0.101 | -0.310 | |
| Operating Cash Flow Sales Ratio | -2.470 | -5.467 | -0.395 | 0.370 | -1.278 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.043 | 1.026 | 1.226 | -1.173 | 1.706 | |
| Debt Service Coverage Ratio | -0.240 | 0.000 | 0.000 | 0.000 | -100.595 | |
| Interest Coverage Ratio | -8.774 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -24.025 | 0.000 | 0.000 | 0.000 | -28.976 | |
| Operating Cash Flow Coverage Ratio | -1.174 | -2.151 | -0.864 | 0.126 | -0.449 | |
| Capital Expenditure Coverage Ratio | -23.090 | -38.816 | -4.423 | 0.460 | -1.416 | |
| Dividend Paid And Capex Coverage Ratio | -23.090 | -38.816 | -4.423 | 0.460 | -1.416 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -196.248 | -5.414 | -16.526 | -9.887 | -20.455 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 84.0% | ▲562.7% | ▲294.8% |
| Ebit Margin | -25.9% | ▲567.1% | ▲290.2% |
| Ebitda Margin | -10.0% | ▲548.5% | ▲287.5% |
| Operating Profit Margin | -274.6% | ▲379.7% | ▲183.1% |
| Pretax Profit Margin | -57.2% | ▲535.8% | ▲316.5% |
| Continuous Operations Profit Margin | -57.2% | ▲535.9% | ▲317.7% |
| Net Profit Margin | -57.2% | ▲535.9% | ▲317.7% |
| Bottom Line Profit Margin | -57.2% | ▲535.9% | ▲317.7% |
| Current Ratio | 13.088 | ▲8.265 | ▲6.157 |
| Quick Ratio | 13.088 | ▲8.265 | ▲6.157 |
| Solvency Ratio | -0.238 | ▲0.721 | ▲0.251 |
| Cash Ratio | 3.043 | ▲1.494 | ▲0.967 |
| Price To Earnings Ratio | -34.222 | ▼-28.807 | ▼-18.474 |
| Price To Earnings Growth Ratio | 0.416 | ▲0.448 | ▲0.760 |
| Forward Price To Earnings Growth Ratio | 0.416 | ▲0.448 | ▲0.760 |
| Price To Earnings Diluted Ratio | -34.222 | ▼-28.807 | ▼-18.474 |
| Price To Earnings Diluted Growth Ratio | 0.416 | ▲0.448 | ▲0.760 |
| Price To Book Ratio | 2.214 | ▼-0.569 | ▼-1.198 |
| Price To Sales Ratio | 19.619 | ▼-12.519 | ▼-20.579 |
| Price To Free Cash Flow Ratio | -7.615 | ▼-1.884 | ▲27.129 |
| Price To Operating Cash Flow Ratio | -7.944 | ▼-2.066 | ▼-11.229 |
| Debt To Assets Ratio | 0.198 | ▲0.052 | ▲0.059 |
| Debt To Equity Ratio | 0.237 | ▲0.017 | ▲0.026 |
| Debt To Capital Ratio | 0.192 | ▲0.011 | ▲0.018 |
| Long Term Debt To Capital Ratio | 0.101 | ▲0.101 | ▲0.080 |
| Financial Leverage Ratio | 1.196 | ▼-0.309 | ▼-0.364 |
| Working Capital Turnover Ratio | 0.150 | ▲0.075 | ▼-0.005 |
| Operating Cash Flow Ratio | -3.560 | ▼-1.653 | ▼-2.280 |
| Operating Cash Flow Sales Ratio | -2.470 | ▲2.997 | ▼-0.622 |
| Free Cash Flow Operating Cash Flow Ratio | 1.043 | ▲0.018 | ▲0.278 |
| Debt Service Coverage Ratio | -0.240 | ▼-0.240 | ▲19.927 |
| Interest Coverage Ratio | -8.774 | ▼-8.774 | ▼-7.019 |
| Short Term Operating Cash Flow Coverage Ratio | -24.026 | ▼-24.026 | ▼-13.425 |
| Operating Cash Flow Coverage Ratio | -1.174 | ▲0.977 | ▼-0.272 |
| Capital Expenditure Coverage Ratio | -23.090 | ▲15.726 | ▼-9.633 |
| Dividend Paid And Capex Coverage Ratio | -23.090 | ▲15.726 | ▼-9.633 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -196.248 | ▼-190.834 | ▼-146.542 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $2.74B | $2.04B | $2.10B | $2.74B | $5.12B | |
| Enterprise value | $2.74B | $1.92B | $1.84B | $2.68B | $4.71B | |
| EV / Sales | 19.61x | 30.24x | 4.86x | 44.07x | 90.77x | |
| EV / Op. cash flow | -7.94x | -5.53x | -12.31x | 119.17x | -71.01x | |
| EV / Free cash flow | -7.61x | -5.39x | -10.04x | -101.59x | -41.62x | |
| EV / EBITDA | -196.25x | -5.41x | -16.53x | -9.89x | -20.45x | |
| Net debt / EBITDA | 0.08x | 0.34x | 2.37x | 0.20x | 1.79x | |
| Current ratio | 13.09x | 4.82x | 5.89x | 4.89x | 5.96x | |
| Income quality | 4.31x | 0.92x | 1.13x | -0.08x | 0.18x | |
| Graham net-net | $10 | $6 | $9 | $7 | $8 | |
| Tax burden | 100.0% | 100.0% | 101.0% | 101.2% | 100.0% | |
| Interest burden | 220.6% | 100.0% | 100.0% | 100.0% | 156.1% | |
| Working capital | $1.17B | $696.1M | $1.01B | $869.3M | $1.06B | |
| Invested capital | $1.38B | $912.4M | $1.24B | $1.10B | $1.25B | |
| Return on assets | -5.4% | -34.1% | -9.1% | -21.5% | -25.1% | |
| Operating ROA | -29.7% | -32.4% | -12.6% | -24.0% | -40.8% | |
| Return on tangible assets | -5.4% | -34.1% | -9.1% | -21.5% | -25.1% | |
| Return on equity | -6.5% | -51.4% | -13.5% | -39.4% | -44.8% | |
| Return on invested capital | -27.4% | -44.4% | -13.9% | -30.0% | -30.9% | |
| Return on capital employed | -27.7% | -45.1% | -14.1% | -30.3% | -31.1% | |
| Earnings yield | -2.9% | -18.5% | -6.3% | -10.6% | -7.2% | |
| Free cash flow yield | -13.1% | -17.4% | -8.7% | -1.0% | -2.2% | |
| Capex / Op. cash flow | -4.3% | -2.6% | -22.6% | 217.3% | -70.6% | |
| Capex / Depreciation | 67.0% | 40.8% | 168.6% | 346.0% | 628.3% | |
| Capex / Sales | 10.7% | 14.1% | 8.9% | 80.4% | 90.3% | |
| SG&A / Sales | 81.4% | 175.6% | 30.9% | 144.1% | 110.4% | |
| R&D / Sales | 293.1% | 578.7% | 115.8% | 511.5% | 746.6% | |
| Stock comp / Sales | 67.4% | 190.0% | 26.1% | 138.4% | 84.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 2112d | |
| Days payables outstanding | 168d | 4d | 0d | 11d | 12d | |
| Operating cycle | 0d | 0d | 0d | 0d | 2112d | |
| Cash conversion cycle | -168d | -4d | 0d | -11d | 2100d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years